Your browser doesn't support javascript.
loading
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction.
England, Elizabeth; Rees, D Gareth; Scott, Ian Christopher; Carmen, Sara; Chan, Denice T Y; Chaillan Huntington, Catherine E; Houslay, Kirsty F; Erngren, Teodor; Penney, Mark; Majithiya, Jayesh B; Rapley, Laura; Sims, Dorothy A; Hollins, Claire; Hinchy, Elizabeth C; Strain, Martin D; Kemp, Benjamin P; Corkill, Dominic J; May, Richard D; Vousden, Katherine A; Butler, Robin J; Mustelin, Tomas; Vaughan, Tristan J; Lowe, David C; Colley, Caroline; Cohen, E Suzanne.
Afiliación
  • England E; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Rees DG; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Carmen S; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Chan DTY; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Chaillan Huntington CE; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Houslay KF; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Erngren T; Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Penney M; Early Oncology DMPK, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Majithiya JB; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Rapley L; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Sims DA; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Hollins C; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Hinchy EC; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Strain MD; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Kemp BP; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Corkill DJ; Bioscience In Vivo, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • May RD; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Vousden KA; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Butler RJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Mustelin T; Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Vaughan TJ; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Lowe DC; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Colley C; Biologics Engineering, R&D, AstraZeneca, Cambridge, UK.
  • Cohen ES; Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. suzanne.cohen@astrazeneca.com.
Sci Rep ; 13(1): 9825, 2023 06 17.
Article en En | MEDLINE | ID: mdl-37330528
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteína 1 Similar al Receptor de Interleucina-1 / Inflamación Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteína 1 Similar al Receptor de Interleucina-1 / Inflamación Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido